Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count
Open Access
- 1 January 2013
- journal article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 6 (1) , 11
Abstract
The FSH starting dose is usually chosen according to women’s age, anamnesis, clinical criteria and markers of ovarian reserve. Currently used markers include antral follicle count (AFC), which is considered to have a very high performance in predicting ovarian response to FSH. The objective of the present study to elaborate a nomogram based on AFC for the calculation of the appropriate FSH starting dose in IVF cycles.Keywords
This publication has 29 references indexed in Scilit:
- Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocolsReproductive Biology and Endocrinology, 2012
- Age-specific nomogram for the decline in antral follicle count throughout the reproductive periodFertility and Sterility, 2011
- The antral follicle count: practical recommendations for better standardizationFertility and Sterility, 2010
- Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)Human Reproduction Update, 2009
- Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulationHuman Reproduction Update, 2007
- Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle countFertility and Sterility, 2007
- A systematic review of tests predicting ovarian reserve and IVF outcomeHuman Reproduction Update, 2006
- Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patientsCurrent Medical Research and Opinion, 2006
- Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in “standard” patients treated with 150 IU/day during the first cycleActa Obstetricia et Gynecologica Scandinavica, 2004
- A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cyclesFertility and Sterility, 2001